-
Something wrong with this record ?
Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission
J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, P. Hanova, M. Klein, H. Mann, O. Sleglova, M. Olejarova, S. Forejtova, O. Ruzickova, J. Vencovsky, K. Pavelka, L. Senolt,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- C-Reactive Protein analysis MeSH
- Adult MeSH
- Leukocyte L1 Antigen Complex blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Arthritis, Rheumatoid blood diagnostic imaging MeSH
- Neoplasm, Residual MeSH
- Aged MeSH
- Ultrasonography MeSH
- Inflammation blood diagnostic imaging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: Clinical remission in some patients with rheumatoid arthritis (RA) may be associated with ongoing synovial inflammation that is not always detectable on clinical examination or reflected by laboratory tests but can be visualized by musculoskeletal ultrasound. The goal of our study was to determine the levels of serum calprotectin, a major leukocyte protein, in patients with RA in clinical remission and to investigate the ability of serum calprotectin levels to distinguish patients in ultrasound-defined remission from those with residual ultrasound subclinical inflammation. METHODS: Seventy RA patients in clinical remission underwent clinical and ultrasound examination. Ultrasound examination was performed according to the German US7 score. Ultrasound remission was defined as grey scale (GS) range 0-1 and power Doppler (PD) range 0. The levels of serum calprotectin and C-reactive protein (CRP) were determined. The discriminatory capacity of calprotectin and CRP in detecting residual ultrasound inflammation was assessed using ROC curves. RESULTS: The total number of patients fulfilling the DAS28-ESR, DAS28-CRP, SDAI and CDAI remission criteria was 58, 67, 32 and 31, respectively. Residual synovial inflammation was found in 58-67% of the patients who fulfilled at least one set of clinical remission criteria. Calprotectin levels were significantly higher in patients with residual synovial inflammation than in those with ultrasound-defined remission (mean 2.5±1.3 vs. 1.7±0.8 μg/mL, p<0.005). Using ultrasound-defined remission criteria, calprotectin had an AUC of 0.692, p<0.05 using DAS28-ESR remission criteria and an AUC of 0.712, p<0.005 using DAS28-CRP remission criteria. Calprotectin correctly distinguished ultrasound remission from subclinical activity in 70% of patients. CRP (AUC DAS28-ESR = 0.494, p = NS; AUC DAS28-CRP = 0.498, p = NS) had lower and insignificant discriminatory capacity. CONCLUSION: The present study demonstrates the potential of calprotectin to distinguish RA patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023512
- 003
- CZ-PrNML
- 005
- 20170720122250.0
- 007
- ta
- 008
- 170720s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0165498 $2 doi
- 035 __
- $a (PubMed)27832086
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hurnakova, Jana $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission / $c J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, P. Hanova, M. Klein, H. Mann, O. Sleglova, M. Olejarova, S. Forejtova, O. Ruzickova, J. Vencovsky, K. Pavelka, L. Senolt,
- 520 9_
- $a OBJECTIVE: Clinical remission in some patients with rheumatoid arthritis (RA) may be associated with ongoing synovial inflammation that is not always detectable on clinical examination or reflected by laboratory tests but can be visualized by musculoskeletal ultrasound. The goal of our study was to determine the levels of serum calprotectin, a major leukocyte protein, in patients with RA in clinical remission and to investigate the ability of serum calprotectin levels to distinguish patients in ultrasound-defined remission from those with residual ultrasound subclinical inflammation. METHODS: Seventy RA patients in clinical remission underwent clinical and ultrasound examination. Ultrasound examination was performed according to the German US7 score. Ultrasound remission was defined as grey scale (GS) range 0-1 and power Doppler (PD) range 0. The levels of serum calprotectin and C-reactive protein (CRP) were determined. The discriminatory capacity of calprotectin and CRP in detecting residual ultrasound inflammation was assessed using ROC curves. RESULTS: The total number of patients fulfilling the DAS28-ESR, DAS28-CRP, SDAI and CDAI remission criteria was 58, 67, 32 and 31, respectively. Residual synovial inflammation was found in 58-67% of the patients who fulfilled at least one set of clinical remission criteria. Calprotectin levels were significantly higher in patients with residual synovial inflammation than in those with ultrasound-defined remission (mean 2.5±1.3 vs. 1.7±0.8 μg/mL, p<0.005). Using ultrasound-defined remission criteria, calprotectin had an AUC of 0.692, p<0.05 using DAS28-ESR remission criteria and an AUC of 0.712, p<0.005 using DAS28-CRP remission criteria. Calprotectin correctly distinguished ultrasound remission from subclinical activity in 70% of patients. CRP (AUC DAS28-ESR = 0.494, p = NS; AUC DAS28-CRP = 0.498, p = NS) had lower and insignificant discriminatory capacity. CONCLUSION: The present study demonstrates the potential of calprotectin to distinguish RA patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a revmatoidní artritida $x krev $x diagnostické zobrazování $7 D001172
- 650 _2
- $a C-reaktivní protein $x analýza $7 D002097
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x krev $x diagnostické zobrazování $7 D007249
- 650 _2
- $a leukocytární L1-antigenní komplex $x krev $7 D039841
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a reziduální nádor $7 D018365
- 650 _2
- $a ultrasonografie $7 D014463
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hulejova, Hana $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic.
- 700 1_
- $a Hanova, Petra $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Klein, Martin $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Sleglova, Olga $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Olejarova, Marta $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Forejtova, Sarka $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Ruzickova, Olga $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Senolt, Ladislav $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 11 (2016), s. e0165498
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27832086 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170720122743 $b ABA008
- 999 __
- $a ok $b bmc $g 1239193 $s 984425
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 11 $c 11 $d e0165498 $e 20161110 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20170720